Bristol-Myers Squibb   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Brooklyn New York United States (1858)

Organization Overview

First Clinical Trial
1995
NCT00002349
First Marketed Drug
1945
tubocurarine (curare)
First NDA Approval
1950
Insulin, bovine
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Adnexus, A Bristol-Myers Squibb R&D Company | Bristol-Mayers Squibb | Bristol-Meyers Squibb & Pfizer | BRISTOL MYERS | Bristol-Myers K.K. | Bristol-Myers Squibb | BRISTOL MYERS SQUIBB | BRISTOL-MYERS SQUIBB | Bristol-Myers-Squibb/Astra-Zeneca | Bristol-Myers Squibb (BMS) | Bristol Myers Squibb Co. and Ono Pharmaceutical Co., Ltd | Bristol-Myers Squibb Company | Bristol Myers Squibb Company (BMS) | Bristol-Myers Squibb, Korea | Bristol-Myers Squibb Research and Development | Bristol-Myers Suibb | Briston-Myers Squibb | Celegene/BMS | Celgene a wholly owned subsidiary of BMS | Celgene-BMS | Celgene Corporation, a Bristol-Myers Squibb Company | COMBE | Juno Therapeutics, Inc. a Bristol Myer-Squibb Company | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Medical Department, Bristol-Myers Squibb